Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Aditxt Inc (ADTX)

Aditxt Inc (ADTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 561
  • Shares Outstanding, K 239
  • Annual Sales, $ 930 K
  • Annual Income, $ -27,650 K
  • 60-Month Beta 1.29
  • Price/Sales 0.89
  • Price/Cash Flow N/A
  • Price/Book 0.04
Trade ADTX with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -3.33
  • Number of Estimates 1
  • High Estimate -3.33
  • Low Estimate -3.33
  • Prior Year -52.40
  • Growth Rate Est. (year over year) +93.65%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.14 +3.74%
on 04/22/24
5.45 -59.27%
on 04/02/24
-0.92 (-29.30%)
since 03/22/24
3-Month
2.14 +3.74%
on 04/22/24
5.45 -59.27%
on 04/02/24
-1.81 (-44.91%)
since 01/22/24
52-Week
2.14 +3.74%
on 04/22/24
68.08 -96.74%
on 08/31/23
-29.38 (-92.97%)
since 04/21/23

Most Recent Stories

More News
Aditxt Subsidiary Adimune Signs Clinical Trial Agreement with Top Research Institution to Study Stiff Person Syndrome

Aditxt®, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation company focused on therapeutics and technologies that modulate and monitor the immune system, today announces that...

ADTX : 2.22 (-5.53%)
Aditxt (NASDAQ: ADTX) Closes on $1.9M Registered Direct Offering

Aditxt (NASDAQ: ADTX), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, announced that it has closed on its previously announced registered...

ADTX : 2.22 (-5.53%)
Aditxt Announces Closing of $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Aditxt, Inc., (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced...

ADTX : 2.22 (-5.53%)
Aditxt Inc. (NASDAQ: ADTX) Registered Direct Offering Expected to Total $1.9M

Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, has entered into a definitive agreement. The company...

ADTX : 2.22 (-5.53%)
Aditxt (NASDAQ: ADTX) Inks Agreement for 50% Ownership of Global Response Aid

Aditxt (NASDAQ: ADTX), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, has signed an asset purchase agreement with Cellvera Ltd. According...

ADTX : 2.22 (-5.53%)
Aditxt Announces $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that...

ADTX : 2.22 (-5.53%)
Aditxt Signs Asset Purchase Agreement to Acquire Fifty Percent Ownership of Global Response Aid – with Rights to Manufacture and Market Broad-Spectrum Antiviral Drug Avigan

Aditxt,® Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, is pleased to announce...

RDY : 72.15 (+1.42%)
ADTX : 2.22 (-5.53%)
Aditxt (NASDAQ: ADTX) Releases Shareholder Update on Major Programs, M&A Plans

Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, has released a shareholder update outlining its three...

ADTX : 2.22 (-5.53%)
Aditxt Issues Shareholder Update

Aditxt,® Inc, (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, is pleased to provide...

ADTX : 2.22 (-5.53%)
Aditxt Names Media Industry Veteran Maureen Connolly as Chief Content and Engagement Officer

Aditxt, Inc. , (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, is pleased...

ADTX : 2.22 (-5.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Aditx Therapeutics Inc. is a life sciences company. It engages in developing biotechnologies specifically focused on health of the immune system through immune monitoring and reprogramming. Aditx Therapeutics Inc. is based in LOMA LINDA, CA.

See More

Key Turning Points

3rd Resistance Point 2.63
2nd Resistance Point 2.51
1st Resistance Point 2.37
Last Price 2.22
1st Support Level 2.11
2nd Support Level 1.99
3rd Support Level 1.85

See More

52-Week High 68.08
Fibonacci 61.8% 42.89
Fibonacci 50% 35.11
Fibonacci 38.2% 27.33
Last Price 2.22
52-Week Low 2.14

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar